Lilly CEO: Realistic Expectations Needed For Current Wave of Alzheimer’s Treatments

 
• By Sarah Karlin-Smith

Successive waves of Alzhiemer’s therapies are going to be needed, David Ricks said as his company awaits Phase III data on donanemab, the last of three late-stage anti-amyloid drugs to report results.

ocean waves
Further generations of Alzheimer’s treatments will be needed to build on current anti-amyloid drugs, Lilly CEO said • Source: Shutterstock

More from Approval Standards

More from Pathways & Standards